DK2254590T3 - Fremgangsmåder og præparater til oral administration af insulin - Google Patents

Fremgangsmåder og præparater til oral administration af insulin

Info

Publication number: DK2254590T3
Authority: DK; Denmark
Prior art keywords: insulin; preparations; methods; oral administration; oral
Prior art date: 2008-01-08

Application number

DK09700655.5T

Other languages

English (en)

Inventor

Alexander Vol

Orna Gribova

Original Assignee

Oshadi Drug Administration Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-08

Filing date

2009-01-08

Publication date

2013-01-28

2009-01-08 Application filed by Oshadi Drug Administration Ltd filed Critical Oshadi Drug Administration Ltd

2013-01-28 Application granted granted Critical

2013-01-28 Publication of DK2254590T3 publication Critical patent/DK2254590T3/da

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
238000000034 method Methods 0.000 title 1
238000002360 preparation method Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Inorganic Chemistry (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Dispersion Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK09700655.5T 2008-01-08 2009-01-08 Fremgangsmåder og præparater til oral administration af insulin DK2254590T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
IL188647A IL188647A0 (en)	2008-01-08	2008-01-08	Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US8029508P	2008-07-14	2008-07-14
US10202008P	2008-10-02	2008-10-02
PCT/IL2009/000037 WO2009087634A2 (en)	2008-01-08	2009-01-08	Methods and compositions for oral administration of insulin

Publications (1)

Publication Number	Publication Date
DK2254590T3 true DK2254590T3 (da)	2013-01-28

Family

ID=40326402

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK09701269.4T DK2231123T3 (da)	2008-01-08	2009-01-08	Fremgangsmåder og præparater til oral administrationaf protein- og peptidterapimidler
DK09700655.5T DK2254590T3 (da)	2008-01-08	2009-01-08	Fremgangsmåder og præparater til oral administration af insulin

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK09701269.4T DK2231123T3 (da)	2008-01-08	2009-01-08	Fremgangsmåder og præparater til oral administrationaf protein- og peptidterapimidler

Country Status (15)

Country	Link
US (3)	US20100278922A1 (da)
EP (2)	EP2231123B1 (da)
JP (1)	JP5432183B2 (da)
KR (1)	KR101588066B1 (da)
AU (2)	AU2009203529B2 (da)
BR (1)	BRPI0906866A2 (da)
CA (2)	CA2711556A1 (da)
DK (2)	DK2231123T3 (da)
EA (1)	EA018461B1 (da)
ES (2)	ES2397061T3 (da)
IL (3)	IL188647A0 (da)
MX (1)	MX2010007462A (da)
NZ (1)	NZ586374A (da)
WO (2)	WO2009087634A2 (da)
ZA (1)	ZA201004480B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2521295Y2 (ja)	1991-11-13	1996-12-25	シーケーディ株式会社	流体混合器
IL188647A0 (en) *	2008-01-08	2008-11-03	Orina Gribova	Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
AU2010269815B2 (en)	2009-07-09	2015-10-15	Oshadi Drug Administration Ltd.	Matrix carrier compositions, methods and uses
AU2012250872B2 (en) *	2011-05-02	2017-07-13	Millennium Pharmaceuticals, Inc.	Formulation for anti-alpha4beta7 antibody
US20150010527A1 (en)	2012-02-01	2015-01-08	Protalix Ltd.	Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
WO2014031837A1 (en) *	2012-08-22	2014-02-27	The Regents Of The University Of California	Compositions and methods for enhancing sialic acid levels in tissue
HK1216240A1 (zh)	2012-11-14	2016-10-28	W. R. Grace & Co.-Conn.	含有生物活性材料与无序无机氧化物的组合物
EP2950809A4 (en) *	2013-01-29	2016-09-14	Oshadi Drug Administration Ltd	PHARMACEUTICAL COMPOSITIONS FOR THE ORAL TREATMENT OF DIABETES
ES2502691B1 (es) *	2013-09-25	2015-07-07	Sani-Red, S.L.	Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos
EP3065717A1 (en) *	2013-11-04	2016-09-14	Biopharmx, Inc.	Dosage form comprising an active ingredient and a plurality of solid porous microcarriers
US9168211B2 (en) *	2014-03-28	2015-10-27	Johnson & Johnson Consumer Inc.	Method of making an anhydrous, pigmented composition
KR102418550B1 (ko) *	2015-11-03	2022-07-06	삼성전자주식회사	포토 레지스트 패턴 형성 방법 및 이를 이용한 반도체 장치 제조 방법
WO2017141262A1 (en) *	2016-02-19	2017-08-24	Indian Institute Of Technology, Bombay	Orally administrable pharmaceutical preparation containing protein
WO2019059804A1 (ru) *	2017-09-25	2019-03-28	Георгий Георгиевич ЧУМБУРИДЗЕ	Термостабильная композиция, обладающая антивирусной и антибактериальной активностью и ее использование
IT201800007947A1 (it) *	2018-08-07	2020-02-07	Vetagro Int Srl	Metodo per preparare una composizione di aminoacidi per consentire la corrispondenza dei singoli fabbisogni di amminoacidi ad un soggetto in base all'età, al genere, all'attività fisica e alla genetica
KR20210151185A (ko) *	2019-04-11	2021-12-13	알.피.쉐러 테크놀러지즈 엘엘씨	난투과성 단백질, 펩타이드 및 소분자의 경구 전달을 위한 제형
US20220296683A1 (en) *	2019-09-20	2022-09-22	University College Dublin	Oral delivery system
IL293904A (en)	2019-12-17	2022-08-01	9286 3620 Quebec Inc	Oral delivery systems based on in situ forming protein/polysaccharide coacervates
WO2021155042A1 (en)	2020-01-28	2021-08-05	Genentech, Inc.	Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer
CA3159988C (en)	2020-07-15	2023-09-19	Bernard Schachtel	Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
US20240315972A1 (en)	2021-07-12	2024-09-26	Zidkiyahu Simenhaus	Protein containing bio-active compositions comprising cellulose microparticle carriers
EP4536684A1 (en)	2022-06-13	2025-04-16	B.A.I. Laboratories, LLC	Interleukin-13 binding cyclic oligopeptides and methods of use thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3252859A (en) *	1962-10-24	1966-05-24	Masti Kure Company Inc	Colloidal silica-oil composition and method of using same
US6551576B1 (en)	1989-12-22	2003-04-22	Bristol-Myers Squibb Medical Imaging, Inc.	Container with multi-phase composition for use in diagnostic and therapeutic applications
ES2027518A6 (es)	1990-12-18	1992-06-01	Andromaco Lab	Procedimiento para la preparacion de nuevas asociaciones no covalentes polisacarido-proteina con actividad farmacologica.
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5260002A (en)	1991-12-23	1993-11-09	Vanderbilt University	Method and apparatus for producing uniform polymeric spheres
US7083572B2 (en)	1993-11-30	2006-08-01	Bristol-Myers Squibb Medical Imaging, Inc.	Therapeutic delivery systems
US20040018236A1 (en) *	1995-05-08	2004-01-29	Robert Gurny	Nanoparticles for oral administration of pharmaceutical agents of low solubility
ES2093562B1 (es)	1995-05-26	1997-07-01	Univ Santiago Compostela	Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6071535A (en)	1996-01-31	2000-06-06	Collaborative Laboratories, Inc.	Lipid vesicles formed with alkylammonium fatty acid salts
US5874105A (en)	1996-01-31	1999-02-23	Collaborative Laboratories, Inc.	Lipid vesicles formed with alkylammonium fatty acid salts
US6322765B1 (en)	1996-02-15	2001-11-27	Wacker-Chemie Gmbh	Process for preparing silicon dioxide
US6120751A (en)	1997-03-21	2000-09-19	Imarx Pharmaceutical Corp.	Charged lipids and uses for the same
US20020039594A1 (en) *	1997-05-13	2002-04-04	Evan C. Unger	Solid porous matrices and methods of making and using the same
US6171586B1 (en) *	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
FR2767718B1 (fr) *	1997-08-28	1999-10-22	Oreal	Emulsion eau-dans-huile comprenant de la silice pyrogenee et un alkylether de polysaccharide
TR199901008T1 (xx)	1997-09-09	2000-02-21	Select Release, L.C.	Kaplanm�� partik�ller, yap�m� ve kullan�m y�ntemleri.
US6638621B2 (en) *	2000-08-16	2003-10-28	Lyotropic Therapeutics, Inc.	Coated particles, methods of making and using
FR2773804B1 (fr) *	1998-01-19	2000-02-18	Sanofi Sa	Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
US6656922B2 (en) *	1998-05-28	2003-12-02	Mediplex Corporation, Korea	Oral delivery of macromolecules
ES2688273T3 (es) *	1999-03-31	2018-10-31	Janssen Pharmaceutica Nv	Almidón pregelatinizado en una formulación de liberación controlada
US6458387B1 (en) *	1999-10-18	2002-10-01	Epic Therapeutics, Inc.	Sustained release microspheres
US7195780B2 (en) *	2002-10-21	2007-03-27	University Of Florida	Nanoparticle delivery system
DE10001172A1 (de) *	2000-01-13	2001-07-26	Max Planck Gesellschaft	Templatieren von Feststoffpartikeln mit Polymermultischichten
JP4631119B2 (ja)	2000-01-28	2011-02-16	Ｊｓｒ株式会社	疎水化コロイダルシリカの製造方法
US7067116B1 (en) *	2000-03-23	2006-06-27	Warner-Lambert Company Llc	Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US6548264B1 (en) *	2000-05-17	2003-04-15	University Of Florida	Coated nanoparticles
UA80248C2 (en)	2000-06-29	2007-09-10		Compounds and compositions for delivering active agents
EP1179349B8 (de) *	2000-08-11	2006-06-07	Lohmann Animal Health GmbH & Co. KG	W/O-Emulsion-Adjuvanszusammensetzungen für Impfstoffe
WO2002032398A2 (en)	2000-10-16	2002-04-25	Massachusetts Institute Of Technology	Lipid-protein-sugar particles for drug delivery
FR2819720B1 (fr) *	2001-01-22	2004-03-12	Fournier Lab Sa	Nouveaux comprimes de fenofibrate
US6698247B2 (en)	2001-05-04	2004-03-02	Corning Incorporated	Method and feedstock for making silica by flame combustion
US6828297B2 (en)	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
JP2005511629A (ja) *	2001-11-20	2005-04-28	アドバンストインハレーションリサーチ，インコーポレイテッド	持続作用生成物送達用組成物
US20030235619A1 (en)	2001-12-21	2003-12-25	Christine Allen	Polymer-lipid delivery vehicles
AU2002351626A1 (en) *	2001-12-21	2003-07-15	Celator Technologies Inc.	Improved polymer-lipid delivery vehicles
US20030198666A1 (en) *	2002-01-07	2003-10-23	Richat Abbas	Oral insulin therapy
EP1474108A2 (en) *	2002-01-09	2004-11-10	Enzrel, Inc.	Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
WO2003066859A2 (en)	2002-02-07	2003-08-14	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Amino acid sequences capable of facilitating penetration across a biological barrier
US7244498B2 (en) *	2002-06-12	2007-07-17	Tda Research, Inc.	Nanoparticles modified with multiple organic acids
US7090868B2 (en)	2002-09-13	2006-08-15	University Of Florida	Materials and methods for drug delivery and uptake
AU2004204727B8 (en)	2003-01-06	2006-11-09	Emisphere Technologies, Inc.	Night-time oral insulin therapy
US20040242729A1 (en) *	2003-05-30	2004-12-02	3M Innovative Properties Company	Stabilized particle dispersions containing surface-modified inorganic nanoparticles
WO2005094785A2 (en)	2003-09-17	2005-10-13	Chiasma, Ltd.	Compositions capable of facilitating penetration across a biological barrier
EP1680087A1 (en) *	2003-10-31	2006-07-19	Teva Pharmaceutical Industries Limited	Nanoparticles for drug delivery
KR100638041B1 (ko) *	2003-12-24	2006-10-23	주식회사 삼양사	수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
CA2563533C (en)	2004-04-15	2013-10-01	Shmuel A. Ben-Sasson	Compositions capable of facilitating penetration across a biological barrier
US7288134B2 (en) *	2004-09-10	2007-10-30	International Business Machines Corporation	Dumbbell-like nanoparticles and a process of forming the same
US7282194B2 (en)	2004-10-05	2007-10-16	Gp Medical, Inc.	Nanoparticles for protein drug delivery
WO2006044660A2 (en) *	2004-10-14	2006-04-27	Vanderbilt University	Functionalized solid lipid nanoparticles and methods of making and using same
WO2006062506A1 (en) *	2004-12-03	2006-06-15	Enzrel, Inc.	Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds
BRPI0614746A2 (pt)	2005-08-09	2011-04-12	University Of Sunderland	partìculas de sìlica hidrofóbicas, métodos de fabricação e uso das mesmas, assim como métodos de detecção e/ou identificação de uma impressão digital ou outra massa ou depósito hidrofóbico
ES2761937T3 (es)	2005-10-24	2020-05-21	Magsense Life Sciences Inc	Método para preparar micropartículas recubiertas con polímero
WO2007056424A2 (en) *	2005-11-07	2007-05-18	Penwest Pharmaceuticals, Co.	Controlled-release emulsion compositions
US20070258889A1 (en)	2005-11-09	2007-11-08	Montana State University	Novel nanoparticles and use thereof
CA2670355A1 (en) *	2005-11-21	2008-04-24	Medivas, Llc	Polymer particles for delivery of macromolecules and methods of use
US20070184076A1 (en) *	2006-02-07	2007-08-09	Unger Evan C	Liquid-filled nanodroplets for anti-cancer therapy
CA2649109A1 (en) *	2006-04-12	2007-10-25	Biodel, Inc.	Rapid acting and long acting insulin combination formulations
IL188647A0 (en) *	2008-01-08	2008-11-03	Orina Gribova	Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
AU2010269815B2 (en) *	2009-07-09	2015-10-15	Oshadi Drug Administration Ltd.	Matrix carrier compositions, methods and uses

2008
- 2008-01-08 IL IL188647A patent/IL188647A0/en unknown
2009
- 2009-01-08 AU AU2009203529A patent/AU2009203529B2/en not_active Ceased
- 2009-01-08 WO PCT/IL2009/000037 patent/WO2009087634A2/en not_active Ceased
- 2009-01-08 DK DK09701269.4T patent/DK2231123T3/da active
- 2009-01-08 US US12/811,859 patent/US20100278922A1/en not_active Abandoned
- 2009-01-08 MX MX2010007462A patent/MX2010007462A/es active IP Right Grant
- 2009-01-08 ES ES09700655T patent/ES2397061T3/es active Active
- 2009-01-08 US US12/811,871 patent/US8936786B2/en not_active Expired - Fee Related
- 2009-01-08 BR BRPI0906866-0A patent/BRPI0906866A2/pt not_active Application Discontinuation
- 2009-01-08 KR KR1020107016634A patent/KR101588066B1/ko not_active Expired - Fee Related
- 2009-01-08 WO PCT/IL2009/000036 patent/WO2009087633A2/en not_active Ceased
- 2009-01-08 CA CA2711556A patent/CA2711556A1/en not_active Abandoned
- 2009-01-08 CA CA2711554A patent/CA2711554C/en not_active Expired - Fee Related
- 2009-01-08 DK DK09700655.5T patent/DK2254590T3/da active
- 2009-01-08 JP JP2010541885A patent/JP5432183B2/ja not_active Expired - Fee Related
- 2009-01-08 EP EP09701269A patent/EP2231123B1/en not_active Not-in-force
- 2009-01-08 EA EA201070827A patent/EA018461B1/ru not_active IP Right Cessation
- 2009-01-08 EP EP09700655A patent/EP2254590B1/en not_active Not-in-force
- 2009-01-08 AU AU2009203530A patent/AU2009203530B2/en not_active Ceased
- 2009-01-08 NZ NZ586374A patent/NZ586374A/en not_active IP Right Cessation
- 2009-01-08 ES ES09701269T patent/ES2398015T3/es active Active
2010
- 2010-06-24 ZA ZA2010/04480A patent/ZA201004480B/en unknown
- 2010-07-06 IL IL206835A patent/IL206835A/en not_active IP Right Cessation
- 2010-07-06 IL IL206834A patent/IL206834A/en not_active IP Right Cessation
2014
- 2014-12-09 US US14/565,416 patent/US9949924B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2009087634A2 (en)	2009-07-16
EP2231123B1 (en)	2012-10-24
AU2009203529B2 (en)	2013-09-05
EA018461B1 (ru)	2013-08-30
IL206835A (en)	2017-09-28
EP2254590B1 (en)	2012-10-10
AU2009203529A1 (en)	2009-07-16
US9949924B2 (en)	2018-04-24
NZ586374A (en)	2011-10-28
US20150147399A1 (en)	2015-05-28
EP2254590A4 (en)	2012-01-25
DK2231123T3 (da)	2013-02-04
US8936786B2 (en)	2015-01-20
IL206834A (en)	2015-09-24
US20100297245A1 (en)	2010-11-25
KR101588066B1 (ko)	2016-01-22
BRPI0906866A2 (pt)	2019-02-26
WO2009087633A3 (en)	2010-03-11
WO2009087634A3 (en)	2010-01-07
AU2009203530A1 (en)	2009-07-16
EP2231123A2 (en)	2010-09-29
AU2009203530B2 (en)	2013-10-24
WO2009087633A2 (en)	2009-07-16
JP2011509287A (ja)	2011-03-24
CA2711554C (en)	2017-01-03
EP2231123A4 (en)	2011-09-07
JP5432183B2 (ja)	2014-03-05
MX2010007462A (es)	2010-08-23
EP2254590A2 (en)	2010-12-01
KR20100119541A (ko)	2010-11-09
CA2711556A1 (en)	2009-07-16
EA201070827A1 (ru)	2010-12-30
HK1148945A1 (en)	2011-09-23
ES2398015T3 (es)	2013-03-13
IL206834A0 (en)	2010-12-30
ZA201004480B (en)	2011-09-28
US20100278922A1 (en)	2010-11-04
ES2397061T3 (es)	2013-03-04
IL188647A0 (en)	2008-11-03
IL206835A0 (en)	2010-12-30
CA2711554A1 (en)	2009-07-16

Publication	Publication Date	Title
DK2254590T3 (da)	2013-01-28	Fremgangsmåder og præparater til oral administration af insulin
DK2275086T3 (da)	2012-07-09	Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf
DK2273975T3 (da)	2014-06-30	Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser
DK3622883T3 (da)	2021-07-19	Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger
DK3011975T3 (da)	2021-03-29	Faststofsammensætning til oral administration af farvestoffer og diagnostisk anvendelse deraf
DK3045043T3 (da)	2020-08-03	Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
DK2320911T3 (da)	2014-11-03	Vasokonstriktionspræparater og fremgangsmåder til anvendelse deraf
DK2493474T3 (da)	2019-10-14	Fremgangsmåder og sammensætninger til vedvarende afgivelse af lægemidler
DK3300743T3 (da)	2023-07-24	Fremgangsmåder til indgivelse af vaccine
DK2114531T3 (da)	2012-07-30	Punktpropper og fremgangsmåder til indgivelse af terapeutiske midler
DK2328601T3 (da)	2020-04-14	Linaclotid-holdige formuleringer til oral indgivelse
DK2340042T3 (da)	2014-10-27	Fremgangsmåder og præparater til behandling af cancer
DK2475372T4 (da)	2020-11-30	Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse
DK2173407T3 (da)	2020-04-27	Anordning til indgivelse af lægemiddel
DK2358669T3 (da)	2014-08-25	Alpha-keto-persyrer og fremgangsmåder til fremstilling og anvendelse heraf
DK2413912T3 (da)	2019-06-17	Farmaceutiske formuleringer, der omfatter nitrocatecholderivater, og metoder til fremstilling deraf
BRPI0907077A2 (pt)	2016-07-26	métodos e composições para administração oral de proteínas
DK2413913T3 (da)	2022-06-13	Farmaceutiske formuleringer omfattende nitrocatecholderivater og fremgangsmåder til fremstilling deraf
DK2244783T3 (da)	2020-03-16	Flygtige anæstetiske sammensætninger og fremgangsmåder til anvendelse
HUE047767T2 (hu)	2020-05-28	Macitentánt tartalmazó terápiás készítmények
DK2320740T3 (da)	2014-06-30	Farmaceutiske sammensætninger af clevidipin og fremgangsmåder tilfremstilling af koncentrationer deraf med lave urenhedsgrader
DK2307445T3 (da)	2013-01-14	Fremgangsmåde til fremstilling af caspofungin og mellemforbindelser heraf
DK2413899T3 (da)	2021-04-19	Dentalt anæstetikum omfattende tetracain og en vasokonstriktor til intranasal indgivelse
DK2068885T3 (da)	2014-12-08	D-vitaminpræparater og fremgangsmåde til administration til et menneske
DK2172207T3 (da)	2013-04-08	Farmaceutisk sammensætning til behandling af diabetes og fremgangsmåde til fremstilling heraf